Download PDF
Semin Thromb Hemost 2015; 41(05): 462-467
DOI: 10.1055/s-0035-1550440
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Liver Disease and Hemostatic (Dys)function

Armando Tripodi
1   Department of Clinical Sciences and Community Health, Università degli Studi di Milano and IRCCS Cà Granda Ospedale Maggiore Foundation, Milano, Italy
› Author Affiliations
Further Information

Publication History

Publication Date:
16 June 2015 (online)

    Permissions and Reprints

Abstract

Cirrhosis presents with decreased procoagulant factors as a consequence of the impaired synthetic capacity of the liver. This was taken as evidence to explain the abnormalities of the coagulation tests prothrombin time (PT) and activated partial thromboplastin time (aPTT) and the bleeding events that occur in these patients. It was for long time (and probably is still) common practice to test patients with the PT and to treat those with predefined (but arbitrary) cutoff values with plasma or prohemostatic agents to prevent or stop bleeding. However, anticoagulant factors that contrast the procoagulants are also decreased in cirrhosis. It was therefore postulated that the coagulation balance (i.e., the net result between the action of pro- and anticoagulants) is somewhat rebalanced. Subsequent studies supported this view showing that plasma from cirrhotic patients generates normal amounts of thrombin. In addition, primary hemostasis (i.e., platelet–vessel wall interaction) is rebalanced notwithstanding cirrhosis present with thrombocytopenia. It was shown that increased levels of the adhesive protein von Willebrand factor (a typical feature of cirrhosis) compensate for the low number (function) of platelets. The earlier considerations have been instrumental to help dismantle the old paradigms of cirrhosis as the epitome of the acquired hemorrhagic coagulopathies and the traditional coagulation tests PT and aPTT as suitable predictors of bleeding risk. The demise of the old paradigms and the rise of the new one may have important practical implications for the management of patients with cirrhosis and will be discussed in this chapter.

Keywords

cirrhosis - thrombin generation - hemorrhage - thrombosis
 

  • References

  • 1 Tripodi A. Hemostasis abnormalities in chronic liver failure. In: Gines P, Kamath PS, Arroyo V, , eds. Chronic Liver Failure. New York, NY: Springer Science + Business Media; 2011: 289-303
    CrossrefGoogle Scholar
  • 2 Giannini EG, Savarino V. Thrombocytopenia in liver disease. Curr Opin Hematol 2008; 15 (5) 473-480
    CrossrefPubMedGoogle Scholar
  • 3 Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD ; American Association for the Study of Liver Diseases. Liver biopsy. Hepatology 2009; 49 (3) 1017-1044
    CrossrefPubMedGoogle Scholar
  • 4 Lisman T, Bongers TN, Adelmeijer J , et al. Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology 2006; 44 (1) 53-61
    CrossrefPubMedGoogle Scholar
  • 5 Tripodi A, Primignani M, Chantarangkul V , et al. Thrombin generation in patients with cirrhosis: the role of platelets. Hepatology 2006; 44 (2) 440-445
    CrossrefPubMedGoogle Scholar
  • 6 Tripodi A, Primignani M, Chantarangkul V , et al. Global hemostasis tests in patients with cirrhosis before and after prophylactic platelet transfusion. Liver Int 2013; 33 (3) 362-367
    CrossrefPubMedGoogle Scholar
  • 7 Afdhal NH, Giannini EG, Tayyab G , et al; ELEVATE Study Group. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. N Engl J Med 2012; 367 (8) 716-724
    CrossrefPubMedGoogle Scholar
  • 8 Tripodi A, Primignani M. Nontransfusional approach to increased platelet count in patients with cirrhosis and thrombocytopenia. Hepatology 2013; 58 (3) 1177-1180
    CrossrefPubMedGoogle Scholar
  • 9 Lisman T, Leebeek FWG, de Groot PG. Haemostatic abnormalities in patients with liver disease. J Hepatol 2002; 37 (2) 280-287
    CrossrefPubMedGoogle Scholar
  • 10 Tripodi A, Salerno F, Chantarangkul V , et al. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology 2005; 41 (3) 553-558
    CrossrefPubMedGoogle Scholar
  • 11 Dahlbäck B. Progress in the understanding of the protein C anticoagulant pathway. Int J Hematol 2004; 79 (2) 109-116
    CrossrefPubMedGoogle Scholar
  • 12 Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med 2011; 365 (2) 147-156
    CrossrefPubMedGoogle Scholar
  • 13 Bosch J, Thabut D, Bendtsen F , et al; European Study Group on rFVIIa in UGI Haemorrhage. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. Gastroenterology 2004; 127 (4) 1123-1130
    CrossrefPubMedGoogle Scholar
  • 14 Bosch J, Thabut D, Albillos A , et al; International Study Group on rFVIIa in UGI Hemorrhage. Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: A randomized, controlled trial. Hepatology 2008; 47 (5) 1604-1614
    CrossrefPubMedGoogle Scholar
  • 15 Lodge JP, Jonas S, Jones RM , et al; rFVIIa OLT Study Group. Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation. Liver Transpl 2005; 11 (8) 973-979
    CrossrefPubMedGoogle Scholar
  • 16 Planinsic RM, van der Meer J, Testa G , et al. Safety and efficacy of a single bolus administration of recombinant factor VIIa in liver transplantation due to chronic liver disease. Liver Transpl 2005; 11 (8) 895-900
    CrossrefPubMedGoogle Scholar
  • 17 Tripodi A, Chantarangkul V, Mannucci PM. Acquired coagulation disorders: revisited using global coagulation/anticoagulation testing. Br J Haematol 2009; 147 (1) 77-82
    CrossrefPubMedGoogle Scholar
  • 18 Tripodi A, Chantarangkul V, Primignani M , et al. Thrombin generation in plasma from patients with cirrhosis supplemented with normal plasma: considerations on the efficacy of treatment with fresh-frozen plasma. Intern Emerg Med 2012; 7 (2) 139-144
    PubMedGoogle Scholar
  • 19 Tripodi A, Chantarangkul V, Mannucci PM. The international normalized ratio to prioritize patients for liver transplantation: problems and possible solutions. J Thromb Haemost 2008; 6 (2) 243-248
    CrossrefPubMedGoogle Scholar
  • 20 Trotter JF, Olson J, Lefkowitz J, Smith AD, Arjal R, Kenison J. Changes in international normalized ratio (INR) and model for endstage liver disease (MELD) based on selection of clinical laboratory. Am J Transplant 2007; 7 (6) 1624-1628
    CrossrefPubMedGoogle Scholar
  • 21 Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000; 31 (4) 864-871
    CrossrefPubMedGoogle Scholar
  • 22 Tripodi A, Chantarangkul V, Primignani M , et al. The international normalized ratio calibrated for cirrhosis (INR(liver)) normalizes prothrombin time results for model for end-stage liver disease calculation. Hepatology 2007; 46 (2) 520-527
    CrossrefPubMedGoogle Scholar
  • 23 Bellest L, Eschwège V, Poupon R, Chazouillères O, Robert A. A modified international normalized ratio as an effective way of prothrombin time standardization in hepatology. Hepatology 2007; 46 (2) 528-534
    CrossrefPubMedGoogle Scholar
  • 24 Northup PG, McMahon MM, Ruhl AP , et al. Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism. Am J Gastroenterol 2006; 101 (7) 1524-1528 , quiz 1680
    CrossrefPubMedGoogle Scholar
  • 25 Søgaard KK, Horváth-Puhó E, Grønbaek H, Jepsen P, Vilstrup H, Sørensen HT. Risk of venous thromboembolism in patients with liver disease: a nationwide population-based case-control study. Am J Gastroenterol 2009; 104 (1) 96-101
    CrossrefPubMedGoogle Scholar
  • 26 Primignani M. Portal vein thrombosis, revisited. Dig Liver Dis 2010; 42 (3) 163-170
    CrossrefPubMedGoogle Scholar
  • 27 Villa E, Cammà C, Marietta M , et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology 2012; 143 (5) 1253-60.e1 , 4
    CrossrefPubMedGoogle Scholar
  • 28 Tripodi A, Primignani M, Chantarangkul V , et al. An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis. Gastroenterology 2009; 137 (6) 2105-2111
    CrossrefPubMedGoogle Scholar
  • 29 Dargaud Y, Trzeciak MC, Bordet JC, Ninet J, Negrier C. Use of calibrated automated thrombinography +/- thrombomodulin to recognise the prothrombotic phenotype. Thromb Haemost 2006; 96 (5) 562-567
    Article in Thieme ConnectPubMedGoogle Scholar
  • 30 Tripodi A, Primignani M, Lemma L, Chantarangkul V, Mannucci PM. Evidence that low protein C contributes to the procoagulant imbalance in cirrhosis. J Hepatol 2013; 59 (2) 265-270
    CrossrefPubMedGoogle Scholar
  • 31 Lisman T, Bakhtiari K, Pereboom IT, Hendriks HG, Meijers JC, Porte RJ. Normal to increased thrombin generation in patients undergoing liver transplantation despite prolonged conventional coagulation tests. J Hepatol 2010; 52 (3) 355-361
    CrossrefPubMedGoogle Scholar
  • 32 Gatt A, Riddell A, Calvaruso V, Tuddenham EG, Makris M, Burroughs AK. Enhanced thrombin generation in patients with cirrhosis-induced coagulopathy. J Thromb Haemost 2010; 8 (9) 1994-2000
    CrossrefPubMedGoogle Scholar
  • 33 Tripodi A, Anstee QM, Sogaard KK, Primignani M, Valla DC. Hypercoagulability in cirrhosis: causes and consequences. J Thromb Haemost 2011; 9 (9) 1713-1723
    CrossrefPubMedGoogle Scholar